A Systematic Review on Attenuation of PCSK9 in Relation to Atherogenesis Biomarkers Associated with Natural Products or Plant Bioactive Compounds in In Vitro Studies: A Critique on the Quality and Imprecision of Studies

Int J Environ Res Public Health. 2022 Oct 8;19(19):12878. doi: 10.3390/ijerph191912878.

Abstract

A systematic review was performed to identify all the related publications describing PCSK9 and atherogenesis biomarkers attenuation associated with a natural product and plant bioactive compounds in in vitro studies. This review emphasized the imprecision and quality of the included research rather than the detailed reporting of the results. Literature searches were conducted in Scopus, PubMed, and Science Direct from 2003 until 2021, following the Cochrane handbook. The screening of titles, abstracts, and full papers was performed by two independent reviewers, followed by data extraction and validity. Study quality and validity were assessed using the Imprecision Tool, Model, and Marker Validity Assessment that has been developed for basic science studies. A total of 403 articles were identified and 31 of those that met the inclusion criteria were selected. 13 different atherogenesis biomarkers in relation to PCSK9 were found, and the most studied biomarkers are LDLR, SREBP, and HNF1α. In terms of quality, our review suggests that the basic science study in investigating atherogenesis biomarkers is deficient in terms of imprecision and validity.

Keywords: PCSK inhibitor; PCSK9; atherogenesis; atherosclerosis; endothelial cells; natural products.

Publication types

  • Review
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis*
  • Biological Products*
  • Biomarkers
  • Humans
  • Phytochemicals
  • Proprotein Convertase 9
  • Sterol Regulatory Element Binding Protein 1

Substances

  • Biological Products
  • Biomarkers
  • Phytochemicals
  • Sterol Regulatory Element Binding Protein 1
  • PCSK9 protein, human
  • Proprotein Convertase 9